Merged with Finnish company Oncos Therapeutics in July, establishing a combined company with two promising technology platforms and diversified pipeline Phase II trial TG01 in pancreatic cancer and the preparation of Phase I/II trial ONCOS-102 in mesothelioma progressed as planned Signed agreements with US based Ludwig Cancer Research and the Cancer Research Institute to evaluate ONCOS-102 in combination with other immunotherapies Entered into collaboration with Czech biotech company Sotio to study combination of ONCOS-102 and Sotio’s dendritic cell therapy LYSAKER, Norway, Nov. 26, 2015 — “The combination with Oncos expanded our technology platform, pipeline and market opportunities.
